Boji Medical controlling shareholder reduces stake, triggering equity change reports

Guangzhou Boji Medical & Biotechnological announced that its controlling shareholder, Wang Tingchun, along with his spouse Zhao Lingli and Hengqin Guangjin Meihong Fermi 13th Private Equity Investment Fund, collectively reduced their stake. From June 30, 2021, to December 3, 2025, their combined shareholding decreased from 38.55% to 35.00% of total share capital (or 35.24% after excluding repurchased shares). This reduction triggered the 1% and 5% integer multiples for equity change.

The transactions occurred through block trades and centralized bidding, with cumulative sales of 8,425,800 shares from September 12, 2025, to December 3, 2025. The changes are attributed to various factors including equity incentive plans, equity distributions, share reductions, and directed share issuances. Wang Tingchun holds 26,603,600 pledged shares, representing 19.71% of his current holdings.

The company stated that this equity change will not alter the company's control or negatively impact its ongoing operations. A pre-disclosure announcement regarding a planned reduction of up to 11,486,500 shares (3.00% of the total share capital after excluding repurchased shares) was made on August 22, 2025, with the planned reduction period from September 12, 2025, to December 11, 2025. This plan is yet to be fully implemented.